Bio-Techne Corp Stock News

MINNEAPOLIS, Feb. 11, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 9:20 a.m. EST. A live…

MINNEAPOLIS, Feb. 11, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB Leerink

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors…

S&P Levels To Watch As "Fed Speakers Lunge Around Like ''Short Gamma'' Traders" After the epic melt-up into month-end, during which the world and their pet rabbit was forced to cover or roll any and all downside hedges, the question now is what happens next? Ahead of the now ''common knowledge'' that Friday''s payrolls print is going to be a disaster (potentially a negative number) - and reassurances from various ''experts'' that this will be ''transitory'', Nomura''s Charlie McElligott comments that Fed Speakers are lunging around like short Gamma traders: The Bostic 50bps mis-headline-ing episode over the wknd having to then be walked back yesterday - followed by Feds Daly also then having to clarify early comments made just hours before yesterday as well - are stark reminders that the months ahead are going to get ugly w.r.t. Fed speak being over-interpreted as forward guidance, when in reality, their commentary is merely a reflection of extremely high inflation - and wages - convexity month-to-month.

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q2 2022 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Announces Positive Phase 1 Data For Anktiva In HIV ImmunityBio, Inc. (NASDAQ: IBRX) announ

Techne (TECH) delivered earnings and revenue surprises of 3.30% and 0.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bio-Techne (NASDAQ:TECH) declares $0.32/share quarterly dividend, in line with previous.Forward yield 0.34%Payable Feb. 25; for shareholders of record Feb. 11; ex-div Feb.

Bio-Techne press release (TECH): FQ2 Non-GAAP EPS of $1.88 beats by $0.09.Revenue of $269.28M (+20.1% Y/Y) beats by $2.71M.CEO comment: "Our teams continue to innovate and execute

Techne (TECH) delivered earnings and revenue surprises of 3.30% and 0.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bio-Techne Corporation TECH has posted Q2 FY22 sales of $269.3 million, up 20% Y/Y, beating the consensus of $266.57 million. [LIVE NOW ON YOUTUBE] Click Here to Watch a FREE MASTERCLASS on the Ult

Bio-Techne (NASDAQ:TECH) is scheduled to announce FQ2 earnings results on Tuesday, February 1st, before market open.The consensus EPS Estimate is $1.79 (+10.5% Y/Y) and the

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.